Sino Biopharmaceutical Limited (SBMFF)

Sino Biopharmaceutical Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	9,570	9,452	12,066	10,569	11,259
Short-Term Investments	220.64	1,553	-	569.5	956.01
Trading Asset Securities	5,028	3,113	4,855	4,656	4,217
Cash & Short-Term Investments	14,818	14,118	16,922	15,794	16,432
Cash Growth	4.96%	-16.57%	7.14%	-3.88%	-13.99%
Accounts Receivable	5,013	4,596	4,643	4,285	2,914
Other Receivables	1,787	1,602	1,575	1,164	1,162
Receivables	6,800	6,199	6,219	5,537	4,076
Inventory	2,373	1,993	2,329	1,938	1,880
Prepaid Expenses	694.17	582.57	465.69	234.13	406.58
Other Current Assets	-	912.71	-	-	-
Total Current Assets	24,685	23,806	25,935	23,503	22,794
Property, Plant & Equipment	10,288	9,912	9,251	8,516	8,392
Long-Term Investments	26,337	25,181	25,230	25,169	13,857
Goodwill	915.69	680.45	662.61	647.93	88.93
Other Intangible Assets	271.89	248.49	278.35	291.56	225.35
Long-Term Deferred Tax Assets	516.29	567.01	505.15	334.87	463.37
Long-Term Deferred Charges	1,873	1,980	973.49	772.46	699.36
Other Long-Term Assets	520.8	1,230	1,229	1,308	690.21
Total Assets	65,408	63,605	64,064	60,543	47,210
Accounts Payable	1,497	1,335	1,884	1,795	1,948
Accrued Expenses	7,651	6,716	6,299	5,146	4,190
Short-Term Debt	-	136.13	136.13	136.13	-
Current Portion of Long-Term Debt	7,602	11,136	9,663	6,521	1,553
Current Portion of Leases	28.33	71.49	60.43	64.47	28.7
Current Income Taxes Payable	318.2	271.87	107.46	101.17	60.7
Current Unearned Revenue	253.24	282.6	310.79	238.2	202.22
Other Current Liabilities	2,206	2,658	1,690	1,344	2,961
Total Current Liabilities	19,556	22,607	20,151	15,345	10,944
Long-Term Debt	1,997	1,074	3,934	5,213	12,363
Long-Term Leases	83.39	298.39	324.26	319.95	264.86
Long-Term Unearned Revenue	557.92	548.27	749.07	674.45	608.2
Long-Term Deferred Tax Liabilities	237.55	781.54	831.79	881.59	171.65
Other Long-Term Liabilities	201.9	125.46	131.08	380.78	439.19
Total Liabilities	22,634	25,435	26,121	22,814	24,791
Common Stock	414.38	414.62	414.9	415.44	415.9
Additional Paid-In Capital	12,421	12,443	12,484	12,578	12,691
Retained Earnings	25,281	23,649	28,358	27,215	13,603
Treasury Stock	-2,975	-1,770	-1,432	-689.35	-469.94
Comprehensive Income & Other	-3,180	-4,262	-10,078	-9,228	-9,493
Total Common Equity	31,961	30,474	29,747	30,291	16,747
Minority Interest	10,813	7,695	8,197	7,438	5,672
Shareholders' Equity	42,774	38,170	37,944	37,729	22,420
Total Liabilities & Equity	65,408	63,605	64,064	60,543	47,210
Total Debt	9,711	12,716	14,118	12,254	14,210
Net Cash (Debt)	5,107	1,402	2,804	3,540	2,222
Net Cash Growth	264.34%	-50.00%	-20.81%	59.33%	-78.82%
Net Cash Per Share	0.28	0.08	0.15	0.18	0.12
Filing Date Shares Outstanding	17,924	18,347	18,468	18,699	18,781
Total Common Shares Outstanding	17,924	18,347	18,468	18,699	18,781
Working Capital	5,129	1,199	5,784	8,158	11,851
Book Value Per Share	1.78	1.66	1.61	1.62	0.89
Tangible Book Value	30,773	29,546	28,806	29,352	16,433
Tangible Book Value Per Share	1.72	1.61	1.56	1.57	0.87
Buildings	5,016	4,248	3,871	3,571	3,656
Machinery	8,433	7,628	6,692	6,132	5,546
Construction In Progress	1,701	1,686	1,804	1,426	987.83
Leasehold Improvements	-	-	-	-	0.13

Source: S&P Global Market Intelligence. Standard template. Financial Sources.